Loading company
Gain Therapeutics, Inc.
GANX · Nasdaq · ·
Next earnings: November 11, 2026
$1.69-4.5%Sep 29 close
- 1M
- -4.5%
- 6M
- -12.9%
- 1Y
- -7.1%
- 5Y
- -77.9%
GANX · Nasdaq · ·
Next earnings: November 11, 2026
$1.69-4.5%Sep 29 close
Gain Therapeutics, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2023, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2023 | 3 months toDec 31, 2022 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$4.7M | -$5.8M | +19.51% |
| Profit per share | -$0.11 | -$0.19 | +42.11% |
| Free Cash Flow | -$3.5M | -$5M | +31.23% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter marked an important period of execution for Gain, highlighted by FDA authorization of our IND for rexaceract , which positions us to advance into Phase 2 clinical development,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, rexaceract is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Gain Therapeutics, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Gain Therapeutics, Inc. has no earnings call transcript available.